Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorUniversity Hospital Pilsen

About this trial

The transplantation of allogeneic haematopoietic stem cells (HSCs) can lead to serious complications after transplantation, such as graft-versus-host disease (GvHD), infections and relapse due to immunosuppression. Invariant NKT cells (iNKT cells) play a pivotal role in modulating the immune response and have been demonstrated to be instrumental in the pathogenesis of GvHD, cytomegalovirus (CMV) infection, and relapse. Their levels are associated with the development of these complications. This multicentre study aims to test the feasibility of standardising iNKT cell monitoring and to investigate the association between iNKT cell levels and post-transplant complications.

Eligibility criteria

Qualifiers

Diagnosis: AML (exlusion of secondary disease)

Disease status at time of HSCT: complete remission

Karnofsky performance status: ≥80%

Source of HSC: PBSC

Disqualifiers

Prior transplant

Uncontrolled Malignancy

Trial design

Treatments tested in this trial

  • blood draw

Treatment groups

75 Participants
are divided into 1 treatment group

Sponsors and collaborators